+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“In-Vitro Fertilization (IVF) Market To Reach $45.0 Billion By 2029 says Visiongain report”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the In-Vitro Fertilization (IVF) Market Report: Forecasts by Instrument (Culture Media, Disposable Devices, Capital Equipment), by Treatment (Fresh Nondonor, Frozen Nondonor, Fresh Donor, Frozen donor), by Application (Fertility Clinics, Hospitals, Others) plus analysis of leading companies operating in the global In-Vitro Fertilization market.

The global In-Vitro Fertilization market size was valued at $17.1 billion in 2019 and is expected to generate market revenue of $45.0 billion by the end of 2029 with a compound annual growth rate of 10.1%. Growing development of advanced technologies coupled with rising prevalence of infertility is expected to spur the market over the projected period. In-Vitro Fertilization is generally used to treat genetic problems or fertility. Supportive government regulations to encourage sperm freezing to stop chances of multiple pregnancies is projected to increase market concentration of In-Vitro Fertilization over the coming years. Additionally, technological advancement to enable pre identification of problems and diseases is expected to spur the market growth.

According to World Health Organization, One in every four couples in developing countries such as India, China, Brazil, Argentina, Peru, African countries, and Colombia had been found to be affected by infertility. Additionally, according to the American Society for Reproductive Medicine (ASRM), in 2018, infertility accounted for more than 7 million women in North America. Moreover, average age of marriage in developing as well as developed countries has increased over the past few years by virtue of increasing working population and increasing focus towards careers and the trends is expected to continue over the coming years.

Asia Pacific dominated overall In-Vitro Fertilization industry in 2018. Growing population, developing healthcare infrastructure in Malaysia, Indonesia, Singapore, and India is expected to prompted manufacturers to adopt plant expansion strategy. Moreover, availability of advanced technology in India, China, and Japan and low cost of treatment as compared to U.S. and European countries is expected to increase market reach over the coming years.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever